With telaglenastat facing a risky trial readout Calithera picks up two bargain-basement oncology projects to pivot to.
Astrazeneca’s Himalaya study is a surprising hit in first-line liver cancer, but competition is already present.
Crispr follows Allogene with backing for off-the-shelf Car-T therapy – and adds big concerns over lack of durability.
Merus regains some lost pride while Bicycle rides to even greater heights.
Turning Point and Repare are left nursing heavy losses, while Relay just about weathers a storm.
Little is known about yesterday’s clinical hold on Allogene’s entire pipeline, but chromosomal abnormalities hint at a worst-case scenario.
The young biotech is well placed to deliver its first pivotal win, but investor focus might lie elsewhere.
2021 is on track to beat last year’s monster haul, but the IPO window could finally be closing.